Weekly Investment Analysts’ Ratings Changes for Accolade (ACCD)

Several brokerages have updated their recommendations and price targets on shares of Accolade (NASDAQ: ACCD) in the last few weeks:

• 10/11/2024 – Accolade had its price target lowered by analysts at Wells Fargo & Company from $7.00 to $6.00. They now have an “equal weight” rating on the stock.
• 10/9/2024 – Accolade had its price target lowered by analysts at Stephens from $10.00 to $8.00. They now have an “overweight” rating on the stock.
• 10/9/2024 – Accolade had its price target lowered by analysts at Barclays PLC from $5.50 to $5.00. They now have an “equal weight” rating on the stock.
• 10/9/2024 – Accolade had its price target lowered by analysts at Canaccord Genuity Group Inc. from $13.00 to $7.00. They now have a “buy” rating on the stock.
• 10/9/2024 – Accolade had its price target lowered by analysts at Truist Financial Co. from $9.00 to $7.50. They now have a “buy” rating on the stock.
• 10/7/2024 – Accolade had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.

Accolade Price Performance

Shares of NASDAQ:ACCD opened at $3.38 on Tuesday. The firm has a market cap of $270.43 million, a price-to-earnings ratio of -2.91 and a beta of 1.99. The firm has a fifty day moving average price of $3.93 and a 200 day moving average price of $5.20. Accolade, Inc. has a fifty-two week low of $3.13 and a fifty-two week high of $15.36. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.80 and a current ratio of 2.72.

Accolade (NASDAQ:ACCD) last released its quarterly earnings data on Tuesday, October 8th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.14. Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%. The business had revenue of $106.40 million during the quarter, compared to the consensus estimate of $104.87 million. During the same quarter in the prior year, the firm earned ($0.43) EPS. The business’s revenue was up 9.8% on a year-over-year basis. As a group, sell-side analysts expect that Accolade, Inc. will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Accolade

Large investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC purchased a new position in shares of Accolade in the first quarter valued at $87,000. Principal Financial Group Inc. purchased a new position in shares of Accolade in the 1st quarter worth $259,000. Mckinley Capital Management LLC bought a new stake in shares of Accolade in the 1st quarter worth about $1,155,000. GSA Capital Partners LLP raised its position in shares of Accolade by 102.8% during the 1st quarter. GSA Capital Partners LLP now owns 51,374 shares of the company’s stock valued at $538,000 after buying an additional 26,044 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of Accolade by 1.7% during the 1st quarter. Swiss National Bank now owns 137,500 shares of the company’s stock valued at $1,441,000 after buying an additional 2,300 shares in the last quarter. Institutional investors own 84.99% of the company’s stock.

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.